Collectively, it can be postulated, based on our findings and others, that gut-derived interventional strategies could be of therapeutic benefit in patients with NAFLD-HCC to reinvigorate CD8+ T cell anti-tumour responses. The gene discussed is CD8A; the disease is hepatocellular carcinoma.